Improved economics of HBsAg screening with commercial radioimmunoassay reagents.
Commercial 125I anti-HBs was processed to yield a sixfold improvement in economy without significant loss of sensitivity or specificity. Additional polystyrene beads were coupled with commercially supplied anti-HBs. The modified assay (Mod-RIA) was compared with commercial RIA, EIA, and RPHA using established HBsAg panels. Mod-RIA was also compared with HEPATEST (RPHA) for screening 71 200 fresh blood donations during an 11.5-month period.
D003365:Costs and Cost Analysis; D006386:Hemagglutination Tests; D006509:Hepatitis B / Q000453:epidemiology; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D008403:Mass Screening / Q000191:economics*; D011863:Radioimmunoassay; D011933:Reagent Kits, Diagnostic / Q000191:economics*; D012606:Scotland
D006514:Hepatitis B Surface Antigens; D011933:Reagent Kits, Diagnostic